DOI QR코드

DOI QR Code

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

  • Sipetic-Grujicic, Sandra Branko (Institute of Epidemiology, Faculty of Medicine, Belgrade University) ;
  • Murtezani, Zafir Hajdar (Clinical Hospital Centre Bezanijska Kosa) ;
  • Neskovic-Konstatinovic, Zora Borivoje (Institute for Oncology and Radiology of Serbia) ;
  • Marinkovic, Jelena Milutin (Institute of Medical Statistics and Informatics, Faculty of Medicine, Belgrade University) ;
  • Kovcin, Vladimir Nikola (Clinical Hospital Centre Bezanijska Kosa) ;
  • Andric, Zoran Gojko (Clinical Hospital Centre Bezanijska Kosa) ;
  • Kostic, Sanja Vladeta (Clinical Hospital Centre Bezanijska Kosa) ;
  • Ratkov, Isidora Stojan (Institute of Epidemiology, Faculty of Medicine, Belgrade University) ;
  • Maksimovic, Jadranka Milutin (Institute of Epidemiology, Faculty of Medicine, Belgrade University)
  • Published : 2014.04.01

Abstract

Background: The aim of this study was to analyze the demographic and clinical characteristics of male breast cancer patients in Serbia, and furthermore to determine overall survival and predictive factors for prognosis. Materials and Methods: In the period of 1996-2006 histopathological diagnosis of breast cancer was made in 84 males at the Institute for Oncology and Radiology of Serbia. For statistical analyses the Kaplan-Meier method, long-rank test and Cox proportional hazards regression model were used. Results: The mean age at diagnosis with breast cancer was $64.3{\pm}10.5$ years with a range from 35-84 years. Nearly 80% of the tumors showed ductal histology. About 44% had early tumor stages (I and II) whereas 46.4% and 9.5% of the male exhibitied stages III and IV, respectively. Only 7.1% of male patients were grade one. One-fifth of all patients had tumors measuring ${\leq}2cm$, and 14.3% larger than 5 cm. Lymph node metastasis was recorded in 40.4% patients and 47% relapse. Estrogen and progesterone receptor expression was positive in 66.7% and 58.3%, respectively. Among 14.3% of individuals tumor was HER2 positive. About two-thirds of all male patients had radical mastectomy (66.7%). Adjuvant hormonal (tamoxifene), systematic chemotherapy (CMF or FAC) and adjuvant radiotherapy were given to 59.5%, 35.7% and 29.8% patients respectively. Overall survival rates at five and ten years for male breast cancer were 55.0% and 43.9%, respectively. According to the multivariate Cox regression predictive model, a lower initial disease stage, a lower tumor grade, application of adjuvant hormone therapy and no relapse occurrence were significant independent predictors for good overall survival. Conclusions: Results of the treatment would be better if disease is discovered earlier and therefore health education and screening are an imperative in solving this problem.

Keywords

Breast cancer;men;survival analysis;predictors

References

  1. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW (1978). Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg, 188, 60-5. https://doi.org/10.1097/00000658-197807000-00010
  2. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7. https://doi.org/10.1002/cncr.20312
  3. Giordano SH, Perkins GH, Broglio K, et al (2005). Adjuvant systemic therapy for male breast carcinoma. Cancer, 104, 2359-64. https://doi.org/10.1002/cncr.21526
  4. Guinee VF, Olsson H, Moller T, et al (1993). The prognosis of breast cancer in males. A report of 335 cases. Cancer, 71, 154-61. https://doi.org/10.1002/1097-0142(19930101)71:1<154::AID-CNCR2820710125>3.0.CO;2-#
  5. Joshi MG, Lee AK, Loda M, et al (1996). Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer, 77, 490-8. https://doi.org/10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#
  6. Lanitis S, Rice AJ, Vaughan A, et al (2008). Diagnosis and management of male breast cancer. World J Surg, 32, 2471-6. https://doi.org/10.1007/s00268-008-9713-7
  7. Mustafa IA, Cole B, Wanebo HJ, Bland KI, Chang HR (1998). Prognostic analysis of survival in small breast cancers. J Am Coll Surg, 186, 562-9. https://doi.org/10.1016/S1072-7515(98)00076-3
  8. Mahdi KM, Nassiri MR, Nasiri K (2013). Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14, 3403-9. https://doi.org/10.7314/APJCP.2013.14.6.3403
  9. Nahleh ZA, Srikantiah R, Safa M, et al (2007). Male breast cancer in the veterans affairs population: a comparative analysis. Cancer, 109, 1471-7. https://doi.org/10.1002/cncr.22589
  10. D'Avanzo B, La Vecchia C (1995). Risk factors for male breast cancer. Br J Cancer, 71, 1359-62. https://doi.org/10.1038/bjc.1995.264
  11. Bruce DM, Heyes SD, Payne S (1996). Male breast cancer: clinicopathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol, 22, 42-6. https://doi.org/10.1016/S0748-7983(96)91418-3
  12. Cimmino VM, Degnim AC, Sabel MS, et al (2004). Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol, 86, 74-7. https://doi.org/10.1002/jso.20045
  13. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H (2008). Male breast cancer: is the scenario changing. World J Surg Oncol, 6, 58-69. https://doi.org/10.1186/1477-7819-6-58
  14. De Perrot M, Deleaval J, Robert J, Spiliopoulos A (2000). Thirty-year experience of surgery for breast carcinoma in men. Eur J Surg, 166, 929-31. https://doi.org/10.1080/110241500447074
  15. Early Breast Cancer Trialist Collaborative group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 365, 1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
  16. Foerster R, Foerster FG, Wulff V, et al (2011). Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer, 11, 335-43. https://doi.org/10.1186/1471-2407-11-335
  17. Fentiman IS, Fourquet A, Hortobagyi GN (2006). Male breast cancer. Lancet, 367, 595-604. https://doi.org/10.1016/S0140-6736(06)68226-3
  18. Goldhirsch A, Wood WC, Coates AS, et al (2011). Panel members. Expert consensus on the primary therapy of early breast cancer. Ann Oncol, 22, 1736-47. https://doi.org/10.1093/annonc/mdr304
  19. Goss PE, Reid C, Pintilie M, Lim R, Miller N (1999). Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years:1955-1996. Cancer, 85, 629-39. https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V
  20. Gomes-Raposo C, Zambrana Tevar F, Sereno Moyano M, Lopez Gomez M, Casado E (2010). Male breast cancer. Cancer Treat Rev, 36, 451-7. https://doi.org/10.1016/j.ctrv.2010.02.002
  21. Agrawal A, Ayantunde A, Rampaul R, Robertson R (2007). Male breast cancer: a review of clinical management. Breast Cancer Res Treat, 103, 11-21. https://doi.org/10.1007/s10549-006-9356-z
  22. Ahmadian M, Samah AA (2013). Application of health behavior theories to breast cancer screening among Asian women. Asian Pac J Cancer Prev, 14, 4005-13. https://doi.org/10.7314/APJCP.2013.14.7.4005
  23. Auvien A, Curtis RE, Ron E (2002). Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst, 94, 1330-2. https://doi.org/10.1093/jnci/94.17.1330
  24. Berg JW, Hutter RV (1995). Breast cancer. Cancer, 75, 257-69. https://doi.org/10.1002/1097-0142(19950101)75:1+<257::AID-CNCR2820751311>3.0.CO;2-Y
  25. Bergmann A, Bello MA, Andrade Costa CR, et al (2012). Male breast cancer: overall survival in a single institution. J Clin Oncol, 30, 93.
  26. Vaizey C, Burke M, Lange M (1999). Carcinoma of the male breast - a review of 91 patients from the Johannesburg Hospital breast clinics. S Afr J Surg, 37, 6-8.
  27. Weiss JR, Moysich KB, Swede H (2005). Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 20-6.
  28. Wolff AC, Hammond ME, Schwartz JN, et al. (2007). American society of clinical oncology/college of American pathologistsguideline recommendations for human growt factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
  29. Xu CY, Jiang ZN, Zhou Y, Li JJ, Huang LM (2013). Estrogen receptor $\alpha$ roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049-52. https://doi.org/10.7314/APJCP.2013.14.7.4049
  30. Yildirim E, Berberoglu U (1998). Male breast cancer: a 22-year experience. Eur J Surg Oncol, 24, 548-52. https://doi.org/10.1016/S0748-7983(98)93608-3
  31. Ros JS, Fletcher JA, Linette GP, et al (2003). The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. The Oncologist, 8, 307-25. https://doi.org/10.1634/theoncologist.8-4-307
  32. Omer Fatih Olmez OF, Evrensel T, Cubukcu E, et al (2013). Prognostic significance of human epidermal receptor (HER)- 3 immunohistochemical expression in patients with metastatic breast cancer. Asian Pac J Cancer Prev, 14, 4115-9. https://doi.org/10.7314/APJCP.2013.14.7.4115
  33. Ravandi-Kashani F, Hayes TG (1998). Male breast cancer: a review of the literature. Eur J Cancer, 34, 1341-7. https://doi.org/10.1016/S0959-8049(98)00028-8
  34. Ribeiro G, Swindell R (1992). Adjuvant tamoxifen for male breast cancer. Br J Cancer, 65, 252-4. https://doi.org/10.1038/bjc.1992.50
  35. Salvadori B, Saccozzi R, Manzari A, et al (1994). Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer, 30, 930-5. https://doi.org/10.1016/0959-8049(94)90117-1
  36. Sasco AJ, Lowenfels AB, Pasker-de Jong P (1993). Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer, 53, 538-49. https://doi.org/10.1002/ijc.2910530403
  37. Slamon D, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
  38. Schaub NP, Maloney N, Schneider H, Feliberti E, Perry R (2008). Changes in male breast cancer over a 30-year period. Am Surg, 74, 707-12.
  39. Talluri S, Kakarala R, Karedan T, Kakarala M (2011). Male breast carcinoma in United States: survival rate and determinants of prognosis. J Clin Oncol, 29, 32. https://doi.org/10.1200/JCO.2009.26.4473
  40. Thompson D, Duedal S, Kirner J, et al (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst, 97, 813-22. https://doi.org/10.1093/jnci/dji141
  41. Volkers N (1999). In coping with cancer, gender metters. J Natl Canver Inst, 91, 1712-4. https://doi.org/10.1093/jnci/91.20.1712

Cited by

  1. Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6673
  2. Fitting Cure Rate Model to Breast Cancer Data of Cancer Research Center vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7923
  3. Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1559
  4. Prognostic factors in male breast cancer: a population-based study vol.156, pp.3, 2016, https://doi.org/10.1007/s10549-016-3768-1
  5. Survival analysis for male ductal and lobular breast cancer patients with different stages pp.1744-8301, 2018, https://doi.org/10.2217/fon-2018-0455